Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Mesothelioma Cancer treatment details. Biologic therapy. Chemotherapy. University of Chicago Comprehensive Cancer Center, Chicago, IL, United States



Survival: 15.6 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: Chicago, IL
   
Hospital: University of Chicago Comprehensive Cancer Center
   
Journal: Link
   
Date: 6/2012

Description:
Patients:
This phase II study involved malignant mesothelioma patients who were divided into two separate treatment groups. Group A consisted of 53 patients with a median age of 62 years; 73.6% were male. Group B had 55 patients with a median age of 65 years; 83.6% were male.

Treatment:
Patients in group A were treated with the biologic therapy agent bevacizumab and the chemotherapy agents gemcitabine and cisplatin.

Patients in group B were treated with gemcitabine and cisplatin only.

Toxicities:
The most severe toxicities in group A were of grade 4 and included grade 3-4 neutropenia, thrombocytopenia, high blood pressure, and blood clots.

The most severe toxicities in group B were of grade 4 and included grade 3-4 neutropenia, thrombocytopenia, anemia, and blood clots.

Results:
The median overall survival rates for groups A and B were 15.6 and 14.7 months, respectively.

Support:
Some of the authors of this study receive research funding from the pharmaceutical companies Genentech and Eli Lilly.

Correspondence: Dr. Hedy L. Kindler; email: hkindler@medicine.bsd.uchicago.edu

E-mail to a Friend Email Physician More Information